Table 1 Baseline characteristics of patients involved in the study
Cohort 1 | Cohort 2 Crizotinib stage | Cohort 2 Post-crizotinib stage | |
|---|---|---|---|
Number of cases | 20 | 53 | 53 |
Gender | |||
Male Female | 10 (50%) 10 (50%) | 30 (56.6%) 23 (43.4%) | 30 (56.6%) 23 (43.4%) |
Median age (range) < 65 ≥ 65 | 52 (33–76) 18 (90%) 2 (10%) | 49 (20–68) 50 (94.3%) 3 (5.7%) | 50 (21–69) 49 (92.4%) 4 (7.6%) |
Pathology | |||
Adenocarcinoma Other type | 20 (100%) 0 | 52 (98.1%) 1 (1.9%) | 51 (96.2%) 2 (3.8%) |
Smoking history | |||
Smoker Never smoker | 6 (30%) 14 (70%) | 15 (28.3%) 38 (71.7%) | 15 (28.3%) 38 (71.7%) |
ECOG | |||
0–1 ≥ 2 | 9 (45%) 11 (55%) | 41 (77.4%) 12 (22.6%) | 31 (58.5%) 22 (41.5%) |
Distant metastasis | |||
Yes No | 20 (100%) 0 | 53 (100%) 0 | 53 (100%) 0 |
CNS metastases | |||
Yes No | 6 (30%) 14 (70%) | 11 (20.7%) 42 (79.3%) | 32 (60.4%) 21 (39.6%) |